In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $23.79 down -0.59% from its previous closing price of $23.93. In other words, the price has decreased by -$0.14 from its previous closing price. On the day, 1335462 shares were traded.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on March 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $60.
On May 22, 2023, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $20.
Evercore ISI Downgraded its Outperform to In-line on March 31, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 13 ’24 when MacLean Michael F sold 40,000 shares for $24.52 per share. The transaction valued at 980,760 led to the insider holds 44,093 shares of the business.
Boyce Sarah sold 28,000 shares of RNA for $633,682 on Mar 12 ’24. The President and CEO now owns 112,117 shares after completing the transaction at $22.63 per share. On Mar 12 ’24, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 27,641 shares for $22.03 each. As a result, the insider received 609,017 and left with 14,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 1.91B and an Enterprise Value of 1.32B. For the stock, the TTM Price-to-Sale (P/S) ratio is 198.38 while its Price-to-Book (P/B) ratio in mrq is 3.77. Its current Enterprise Value per Revenue stands at 138.39 whereas that against EBITDA is -5.67.
Stock Price History:
The Beta on a monthly basis for RNA is 0.71, which has changed by 21.63% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $26.24, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 14.97, while the 200-Day Moving Average is calculated to be 9.91.
Shares Statistics:
For the past three months, RNA has traded an average of 1.19M shares per day and 1.59M over the past ten days. A total of 79.28M shares are outstanding, with a floating share count of 70.74M. Insiders hold about 11.26% of the company’s shares, while institutions hold 98.38% stake in the company. Shares short for RNA as of Feb 29, 2024 were 7.77M with a Short Ratio of 6.53, compared to 7.64M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.74% and a Short% of Float of 9.86%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.78 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.95, while EPS last year was -$0.74. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.67 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.71 and -$4.19 for the fiscal current year, implying an average EPS of -$3.2. EPS for the following year is -$3.53, with 7 analysts recommending between -$2.76 and -$4.65.
